A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
Combining the dual sodium glucose cotransporter (SGLT) 1 and 2 inhibitor sotagliflozin with optimized insulin therapy led to sustained reductions in HbA1c levels over 1 year in adults with type 1 diabetes (T1D), according to a study presented at ADA 2018.
Combined treatment with the GLP-1 receptor agonist exenatide and the SGLT-2 inhibitor dapagliflozin appeared to be effective up to 2 years in patients with type 2 diabetes (T2D), the phase III DURATION-8 extension trial has shown.
The sodium glucose co-transporter 2 (SGLT-2) inhibitor canagliflozin does not appear to increase the risk of below-knee lower extremity amputations over other SGLT2 inhibitors or non-SGLT2 inhibitor antihyperglycaemic agents in patients with type 2 diabetes (T2D), but may reduce the risk of hospitalization for heart failure (HHF), according to findings of the US-based OBSERVE-4D* study.
Intensified multipronged treatment in patients with type 2 diabetes (T2D) for 7.8 years is not associated with any significant increase in total costs or in costs per person-year when compared to conventional multipronged treatment over a follow-up of 21.2 years, according to the results of the Steno 2 Study presented at the 78th Scientific Sessions of the American Diabetes Association (ADA 2018).
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
Clinical and academic medicine, particularly in the field of diabetes, are not free of gender disparities, according to an all-female panel of industry leaders held at the recent 78th Scientific Sessions of the American Diabetes Association (ADA 2018).
Acculturation appears to predispose Asian Indian immigrants in the US to type 2 diabetes and cardiovascular disease, with the adoption of American lifestyle behaviours having an impact on glycated haemoglobin and high-density lipoprotein cholesterol levels, according to a study.
Adding the selective SGLT2* inhibitor dapagliflozin to insulin therapy improves HbA1c levels in patients with inadequately controlled type 1 diabetes (T1D), according to the DEPICT-2** study presented at ADA 2018.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.